Correspondence

Retraction

Retraction: Barlogie et al. Duration of Survival in Patients with Myeloma Treated with Thalidomide. N Engl J Med 2008;359:210-2.

N Engl J Med 2008; 359:1410September 25, 2008

Article

To the Editor:

We wish to retract our letter to the editor, “Duration of Survival in Patients with Myeloma Treated with Thalidomide,” which was published in the Journal on July 10, 2008.1 The content of this letter, submitted in February 2008 and accepted by the Journal in March 2008, largely duplicates the data that were published online by Blood on May 20, 2008.2

Bart Barlogie, M.D., Ph.D.
John D. Shaughnessy, Jr., Ph.D.
University of Arkansas for Medical Sciences, Little Rock, AR 72205
barlogiebart@uams.edu

John Crowley, Ph.D.
Cancer Research and Biostatistics, Seattle, WA 98101

2 References

1. 1

   Barlogie B, Shaughnessy JD Jr, Crowley J. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008;359:210-212
   Full Text | Web of Science | Medline

2. 2

   Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008 May 20 (Epub ahead of print). DOI: 10.1182/blood-2008-03-145235.